Using a blend of computer modeling, structural and cell-based studies, scientists at The Wertheim UF Scripps Institute have designed a group of potential diabetes drugs that reprogram insulin-resistant cells into a healthier state while limiting side effect risks of older medications.
An estimated 36 million people in the United States live with Type 2 diabetes, a condition that develops when the body becomes resistant to insulin, the hormone that enables cells to metabolize sugar. About a third of people with this condition also have chronic kidney disease, complicating their treatment options.
Read more about HiPerGator Supercomputer Accelerates Diabetes Drug Discovery.
